Surgical Site Infection (SSI) Drug Pipeline Analysis Report 2025

Surgical site infections are considered one of the dangerous complications of surgical procedures, accounting for nearly 20% of all hospital-acquired infections (HAIs). They have a pooled prevalence of 2.5% to 41.9% worldwide and significantly affect low and middle-income countries, especially patients in intensive care units (ICU). The increasing cases of surgical site infections are augmenting the demand for preventive and therapeutic solutions. Moreover, the rise in antibiotic-resistant bacteria is propelling the need for alternative treatments, thereby driving innovation in the drug pipeline.

Report Coverage

The Surgical Site Infection (SSI) Drug Pipeline Insight Report by the publisher gives comprehensive insights into surgical site infection (SSI) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for surgical site infection (SSI). The surgical site infection (SSI) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The surgical site infection (SSI) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with surgical site infection (SSI) treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to surgical site infection (SSI).

Surgical Site Infection (SSI) Drug Pipeline Outlook

A surgical site infection (SSI) is a type of healthcare-associated infection (HAI) that occurs at the site of surgery. It exposes the patient to substantial healthcare costs as a result of severe morbidity and longer hospital stays along with the increased risk of death. Risk factors for surgical site infection include poor nutritional state, anemia, age, and obesity, among others.

Surgical site infection (SSI) therapeutics include broad-spectrum antibiotics and narrow-spectrum antibiotics targeting the specific pathogen identified through culture and sensitivity testing. Surgical site infection (SSI) emerging drugs like biologics, such as monoclonal antibodies, help in enhancing immune response and prevent infections. Further, the growing focus on non-antibiotic therapies, such as bacteriophage treatments and probiotic-based approaches, to address antibiotic resistance is anticipated to support the drug pipeline expansion in the coming years.

Surgical Site Infection (SSI) Epidemiology

A 2023 systematic review and meta-analysis found the global incidence of surgical site infections (SSIs) to be 2.5%. Subgroup analysis showed an incidence of 2.7% by WHO region and 2.5% by the survey period. The African region reported the highest incidence of surgical site infections. Further, the pooled prevalence is estimated to be 2.5% to 41.9% worldwide.

Surgical Site Infection (SSI) - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of surgical site infection (SSI) drug candidates based on several segmentations including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies (mAbs)
• Peptides
• Antimicrobial Agents
• Other Biologics

By Route of Administration

• Oral
• Parenteral
• Others

Surgical Site Infection (SSI) - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials, with a substantial number of surgical site infection (SSI) drugs undergoing clinical development.

Surgical Site Infection (SSI) - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the surgical site infection (SSI) pipeline analysis include small molecules, monoclonal antibodies (mAbs), peptides, antimicrobial agents, and other biologics. The surgical site infection (SSI) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for surgical site infection (SSI).

Surgical Site Infection (SSI) Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the surgical site infection (SSI) drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed surgical site infection (SSI) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. below is the list of a few players involved in surgical site infection (SSI) clinical trials:

• MinaPharm Pharmaceuticals
• MB PHARMA s.r.o.
• PolyPid Ltd.
• Skye Biologics Holdings, LLC
• Ondine Biomedical Inc.

Surgical Site Infection (SSI) - Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: D-PLEX

Sponsored by PolyPid Ltd., the objective of this randomized clinical trial is to investigate the efficacy and safety of the surgical site infection (SSI) drug candidate D-PLEX in the prevention of post-abdominal surgery incisional infection. The study is under Phase III clinical development and has an estimated 624 participants.

Drug: ActiveMatrix

Baylor College of Medicine is conducting a Phase IV study aimed at examining the efficacy and safety of the investigational drug ActiveMatrix on spinal surgical site infection rate. The clinical trial has enrolled about 275 subjects and is expected to be completed by July 2026.

Reasons To Buy This Report

The Surgical Site Infection (SSI) Drug Report provides a strategic overview of the latest and future landscape of treatments for surgical site infection (SSI). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within surgical site infection (SSI) pipeline insights.

Key Questions Answered in the Surgical Site Infection (SSI) - Pipeline Insight Report

• What is the current landscape of Surgical Site Infection (SSI) disease pipeline drugs?
• Which companies/institutions are developing Surgical Site Infection (SSI) disease emerging drugs?
• How many phase II drugs are currently present in Surgical Site Infection (SSI) disease pipeline drugs?
• Which company is leading the Surgical Site Infection (SSI) disease pipeline development activities?
• What is the current Surgical Site Infection (SSI) disease therapeutic assessment?
• What are the opportunities and challenges present in the Surgical Site Infection (SSI) disease drug pipeline landscape?
• What is the efficacy and safety profile of Surgical Site Infection (SSI) disease pipeline drugs?
• Which companies/institutions are involved in Surgical Site Infection (SSI) disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Surgical Site Infection (SSI) disease?

This product will be delivered within 3-5 business days.